A once-weekly growth hormone therapy improved growth-related endpoints for adolescents with multiple conditions of short ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...

Fu, K.Y., Light, A.R. and Maixner, W. (2001) Long-Lasting Inflammation and Long-Term Hyperalgesia after Subcutaneous Formalin Injection into the Rat Hindpaw. The Journal of Pain, 2, 2-11.

Subcutaneous immunotherapy is a unique therapy for allergic disease because it provides symptomatic relief while modifying the allergic disease by targeting the underlying immunological mechanism.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

The LifeSite Hemodialysis Access System was designed as a totally subcutaneous alternative to hemodialysis catheters. It combines port and catheter technology, allowing immediate use on implantation.

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ...

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy Published Jun 20, 2025 1:00pm EDT ...

"We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients.